论文信息 - KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

TPS507Background: Patients with MIBC who are ineligible for neoadjuvant cisplatin-based chemotherapy receive the standard-of-care treatment of radical cystectomy (RC) and pelvic lymph node dissecti...